pregabalin

Phase 3Completed

0 watching 0 views this week📈 Rising

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Neuralgia, Postherpetic

Conditions

Neuralgia, Postherpetic

Trial Timeline

Jan 12, 2007 → Aug 19, 2008

NCT ID

NCT00424372

About pregabalin

pregabalin is a phase 3 stage product being developed by Pfizer for Neuralgia, Postherpetic. The current trial status is completed. This product is registered under clinical trial identifier NCT00424372. Target conditions include Neuralgia, Postherpetic.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (20)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01773993	Pre-clinical	Completed	Feb 1, 2013	Jul 1, 2017	Pain Associated With Fibromyalgia
NCT01603394	Approved	Terminated	Oct 1, 2012	Jun 1, 2013	Postherpetic Neuralgia
NCT01463306	Phase 3	Completed	Feb 21, 2012	Aug 22, 2019	Epilepsy, Partial Seizures
NCT01298466	Approved	Withdrawn	Feb 1, 2012	Feb 1, 2013	Low Back Pain
NCT01474772	Phase 3	Completed	Oct 1, 2011	Jul 1, 2013	Diabetic Peripheral Neuropathy
NCT01397006	Approved	Withdrawn	Sep 1, 2011	Mar 1, 2014	Fibromyalgia
NCT01020526	Approved	Completed	Sep 1, 2010	Jun 1, 2015	Fibromyalgia
NCT01202227	Phase 3	Completed	Sep 1, 2010	Mar 1, 2012	Spinal Cord Diseases
NCT01226667	Approved	Completed	Jul 1, 2010	Jul 1, 2012	Fibromyalgia
NCT00819988	Phase 3	Completed	May 1, 2009	Oct 1, 2011	Delirium
NCT00596466	Phase 3	Completed	Apr 1, 2008	Dec 1, 2011	Epilepsy
NCT00553280	Phase 3	Completed	Feb 1, 2008	Jan 1, 2010	Diabetic Neuropathy, Painful
NCT01061697	Approved	Completed	Jan 1, 2008	Apr 1, 2010	Cervical Spondylosis
NCT00891397	Pre-clinical	Terminated	Nov 1, 2007	Oct 1, 2010	Complex Regional Pain Syndromes
NCT00448916	Phase 3	Completed	May 1, 2007	Oct 1, 2013	Epilepsies, Partial
NCT00407797	Approved	Terminated	Mar 1, 2007	Aug 1, 2009	Partial Seizures
NCT00424372	Phase 3	Completed	Jan 12, 2007	Aug 19, 2008	Neuralgia, Postherpetic
NCT00407511	Approved	Completed	Jan 1, 2007	Jul 1, 2008	Diabetic Peripheral Neuropathic Pain (DPN)
NCT00346034	Phase 3	Completed	Dec 1, 2006	Feb 1, 2008	Fibromyalgia
NCT00843284	Pre-clinical	Completed	Sep 1, 2006	Mar 1, 2008	Neuropathic Pain

Competing Products

20 competing products in Neuralgia, Postherpetic

See all competitors

Product	Company	Stage	Hype Score
Placebo + DS-5565	Daiichi Sankyo	Pre-clinical	23
QUTENZA	Astellas Pharma	Approved	85
ASP8477 + Placebo	Astellas Pharma	Phase 2	52
E2007 (perampanel) + Placebo	Eisai	Phase 2	52
E2007	Eisai	Phase 2/3	65
KHK6188 + Placebo	Kyowa Kirin	Phase 2	52
ONO-1110 + Placebo	Ono Pharmaceutical	Phase 2	52
Galcanezumab	Eli Lilly	Approved	85
Placebo + Pregabalin SR tablet 165mg/day + Pregabalin SR tablet 330mg/day + Pregabalin SR tablet 660mg/day	Jiangsu Hengrui Medicine	Phase 3	77
ABT-894 + ABT-894 + ABT-894 + placebo + Duloxetine	AbbVie	Phase 2	52
MK-8291 + Placebo	Merck	Phase 1	33
Etoricoxib + Placebo	Merck	Approved	85
Cetuximab + Placebo	Merck	Phase 2	52
ADL5747 + Placebo + Pregabalin	Merck	Phase 2	52
MK0759	Merck	Phase 2	52
MK0686	Merck	Phase 2	52
Comparator: pregabalin + Comparator: Placebo (unspecified)	Merck	Phase 1	33
EMA401 + Placebo	Novartis	Phase 2	52
pregabalin	Pfizer	Approved	84
Lyrica (pregabalin) + Placebo	Pfizer	Approved	84

Other Products from Pfizer